More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue....


More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue. Molecular diagnostic testing revenue rose +20% over the prior year, while revenue from its BRACAnalysis test, which represented 74% of total revenue, grew by 9%. Operating income +26%, while operating margin rose to 37% from 35.5%. Shares +2.5% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs